- Home
- GFL vs ROIV Comparison
GFL vs ROIV Comparison
Compare GFL & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GFL | ROIV |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2B | 14.1B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | GFL | ROIV |
|---|---|---|
| Price | $44.49 | $22.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $56.50 | $24.31 |
| AVG Volume (30 Days) | 1.7M | ★ 5.9M |
| Earning Date | 02-11-2026 | 02-09-2026 |
| Dividend Yield | ★ 0.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 6.65 | N/A |
| Revenue | ★ $5,904,199,182.00 | $20,329,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.24 | $741.42 |
| P/E Ratio | $6.72 | ★ N/A |
| Revenue Growth | ★ 27.49 | N/A |
| 52 Week Low | $40.83 | $8.73 |
| 52 Week High | $52.00 | $23.91 |
Technical Indicators
Market Signals| Indicator | GFL | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 58.51 | 56.31 |
| Support Level | $41.94 | $22.50 |
| Resistance Level | $42.91 | $23.20 |
| Average True Range (ATR) | 1.07 | 0.75 |
| MACD | 0.30 | -0.01 |
| Stochastic Oscillator | 78.61 | 63.73 |
Price Performance
Historical ComparisonAbout GFL GFL Environmental Inc. Subordinate voting shares no par value
GFL Environmental Inc is an environmental services company. Its offerings include non-hazardous solid waste management, infrastructure, soil remediation, and liquid waste management services. Its solid waste management business line, which generates the majority of the revenue, consists of the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste. Its Environmental Services business line includes liquid waste and soil remediation. The company's geographical segments are Canada and the United States. The company derives the majority of its revenue from the United States.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.